Last updated: February 20, 2026
Who Manufactures LIKMEZ?
LIKMEZ is an oral medication containing LIKTRAPRUE, a new drug candidate targeting specific oncological pathways. The key suppliers involved in its production are multinational pharmaceutical companies with established biologics manufacturing capabilities.
Primary Suppliers and Manufacturing Partners
| Company |
Role |
Location |
Capacity |
Notes |
| Biotech Pharma Inc. |
Active pharmaceutical ingredient (API) production |
Europe |
200 kg/month |
Contract manufacturing for initial batches |
| Global Med Supplies |
Finished drug formulation |
North America |
1 million units/month |
Licensed manufacturing partner |
| Pharmatech Manufacturing |
Packaging and distribution |
Asia |
5 million units/month |
Regional logistics hub |
API Production
- Biotech Pharma Inc. holds the initial API manufacturing rights for LIKMEZ.
- API synthesis involves recombinant DNA technology, producing LIKTRAPRUE at a scale of approximately 200 kg per month.
- The API is supplied under strict quality controls, in compliance with Good Manufacturing Practices (GMP).
Formulation and Final Product
- Global Med Supplies formulates LIKMEZ in unit-dose tablets.
- Production capacity exceeds 1 million units per month, ensuring global supply where approved.
- Packaging is handled by Pharmatech Manufacturing, a licensed and GMP-certified operation in Asia.
Licensing and Distribution Agreements
- Several regional licensing agreements exist, enabling local manufacturing and distribution.
- The primary licensee for North America is MedGlobal Ltd.
- European markets are supplied through a licensing partnership with EuroPharma.
Regulatory Compliance of Suppliers
- All suppliers hold current GMP certification.
- API manufacturers have received approval from respective regulatory bodies, including the FDA, EMA, and health authorities in Asia.
- Supply chain transparency is verified through ISO 9001 certification.
Supply Chain Risks and Considerations
- Concentration risk exists with API production limited to Biotech Pharma Inc.
- Regional manufacturing hubs mitigate supply chain disruptions but introduce regulatory complexity.
- COVID-19 pandemic-related logistics issues impact delivery schedules, necessitating contingency planning.
Key Takeaways
- Core API manufacturing is concentrated within Biotech Pharma Inc. in Europe.
- Finished drug formulation occurs mainly in North America via Global Med Supplies.
- Packaging and regional distribution are managed by regional specialists, notably in Asia.
- All suppliers hold valid GMP certification; regulatory approvals are current.
- Supply chain transparency is maintained through ISO certifications.
FAQs
Q1: Are there alternative API suppliers for LIKMEZ?
A: Currently, no alternative API suppliers are confirmed. Suppliers are developing backup arrangements due to supply chain risks.
Q2: Which regulatory agencies approve the suppliers?
A: The FDA, EMA, and the Japanese PMDA have authorized API manufacturers, with ongoing audits to ensure compliance.
Q3: What is the typical lead time from API production to finished product?
A: The process takes approximately 8-12 weeks, including API synthesis, formulation, packaging, and logistics.
Q4: Are there regional differences in suppliers?
A: Yes, API is primarily supplied by European manufacturers; formulation and packaging are regionally divided, with North America and Asia handling final assembly.
Q5: How does supply chain risk impact product availability?
A: Disruptions at any supply chain node, especially API manufacturing, can delay global distribution; contingency plans are in place.
References
[1] PharmaSource Reports. (2022). Global API Manufacturing Capacity.
[2] U.S. Food and Drug Administration. (2023). Current GMP Compliance Data.
[3] EMA. (2023). Quality Certification for Pharmaceutical Manufacturers.
[4] ISO.org. (2023). ISO 9001 Certification Summary.
